[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100263132":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":48,"centralContacts":40,"locations":40,"responsibleParty":53,"collaborators":40,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":40,"acronym":40,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":40,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":74,"whyStopped":40,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":40},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",[8,16,20,24,28,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence 1 (ABC)","OTHER","Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)\n\nThere will be a washout of at least 7 days between the each period.",[13,14,15],"Drug: Fimasartan","Drug: Rosuvastatin","Drug: Fimasartan + Rosuvastatin",{"label":17,"type":10,"description":18,"interventionNames":19},"Sequence 2 (ACB)","Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)\n\nThere will be a washout of at least 7 days between the each period.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Sequence 3 (BAC)","Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)\n\nThere will be a washout of at least 7 days between the each period.",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Sequence 4 (BCA)","Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)\n\nThere will be a washout of at least 7 days between the each period.",[13,14,15],{"label":29,"type":10,"description":30,"interventionNames":31},"Sequence 5 (CAB)","Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)\n\nThere will be a washout of at least 7 days between the each period.",[13,14,15],{"label":33,"type":10,"description":34,"interventionNames":35},"Sequence 6 (CBA)","Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)\n\nThere will be a washout of at least 7 days between the each period.",[13,14,15],[37,42,45],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":40},"DRUG","Fimasartan",null,[9,17,21,25,29,33],{"type":38,"name":43,"description":40,"armGroupLabels":44,"otherNames":40},"Rosuvastatin",[9,17,21,25,29,33],{"type":38,"name":46,"description":40,"armGroupLabels":47,"otherNames":40},"Fimasartan + Rosuvastatin",[9,17,21,25,29,33],[49],{"name":50,"affiliation":51,"role":52},"Laura Sterling, M.D","Celelion, Inc.","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100263132","phase-1-a-clinical-trial-to-evaluate-the-pharmacokinetics-and-safety-of-fimasartan-and-rosuvastatin-in-healthy-male-subjects-100263132",true,"NCT02704702","A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects","Inclusion Criteria:\n\n1. Caucasian male 19-55 years of age.\n2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg\u002Fm2 at screening.\n3. Medically healthy with no clinically significant medical history.\n4. Understands the study procedures in the Informed consent form (ICF), and be willing and able to comply with the protocol.\n\nExclusion Criteria:\n\n1. History or presence of clinically significant medical or psychiatric condition or disease.\n2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).\n3. Seated blood pressure is less than 90\u002F60 mmHg or greater than 140\u002F90 mmHg at screening.\n4. Plasma donation within 7 days prior to the first dose of study drug.\n5. Participation in another clinical trial within 28 days prior to the first dose of study drug(s).","MALE","19 Years","55 Years",{"count":65,"type":66},36,"ACTUAL","INTERVENTIONAL",[69],"PHASE1","The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and rosuvastatin when coadministered or administered alone as a single dose or as multiple doses to healthy male subjects.",[72],"Hypertension",[39],"COMPLETED","2018-02-05",{"date":77,"type":66},"2018-11-02",{"date":79,"type":40},"2016-03",{"date":81,"type":66},"2016-06",{"name":5,"class":6}]